Skip to main content
RYTM
NASDAQ Life Sciences

扩展的3期数据显示Setmelanotide在下丘脑肥胖症中降低体重指数18.8%

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$92.66
Mkt Cap
$6.332B
52W Low
$45.905
52W High
$122.2
Market data snapshot near publication time

summarizeSummary

Rhythm Pharmaceuticals宣布了其针对获得性下丘脑肥胖症患者的Setmelanotide 3期TRANSCEND试验的额外52周数据。扩展的数据集包括142名患者（包括日本和补充队列），展示了体重指数降低的安慰剂校正差异为18.8%。此外，接受Setmelanotide治疗的患者在饥饿评分中平均每周降低2.5分。这些新的、详细的疗效数据进一步加强了Setmelanotide的临床特征，建立在此前宣布的阳性顶线结果之上。该公司的补充新药申请（sNDA）正在FDA审查中，PDUFA目标日期为2026年3月20日，最后的数据包将于2026年3月2日提交给FDA。这个强大的数据包增强了人们对该药物潜在的监管批准和市场接受的信心，使即将到来的PDUFA日期成为一个关键的催化剂。

在该公告发布时，RYTM的交易价格为$92.66，交易所为NASDAQ，所属行业为Life Sciences，市值约为$63.3亿。 52周交易区间为$45.91至$122.20。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RYTM - Latest Insights

RYTM
Apr 03, 2026, 3:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Rhythm Pharma Appoints Biotech Veteran Kimberly Popovits to Board, Mathers Resigns
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Rhythm Pharma's IMCIVREE Receives Positive EU Opinion for Hypothalamic Obesity, Expanding Global Market
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Positive CHMP Opinion for IMCIVREE Expands Rhythm Pharma's European Market Opportunity for Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Mar 20, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, Expanding Market for First-Ever Therapy
Sentiment: Positive
View Wiseek Article
RYTM
Mar 19, 2026, 6:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, First & Only Therapy for Rare Disease
Sentiment: Positive
View Wiseek Article
RYTM
Mar 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise
Sentiment: Negative
View Wiseek Article
RYTM
Mar 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma Reports Strong Additional Phase 3 Data for Setmelanotide in Hypothalamic Obesity Ahead of PDUFA Date
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:31 PM EST
Source: Reuters
Importance Score:
9
Setmelanotide Phase 3 Trial Hits Primary Endpoint with 16.4% BMI Reduction; PDUFA Date Set for March 20
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
9
Expanded Phase 3 Data for Setmelanotide Reveals 18.8% BMI Reduction in Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Feb 26, 2026, 6:11 PM EST
Source: Reuters
Importance Score:
7
Rhythm Pharmaceuticals Files For Mixed Shelf
Sentiment: Negative
View Wiseek Article